CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dyax Corp. (Nasdaq: DYAX) announced today the resignation of Thomas Beck, M.D., as the Company’s President and Chief Operating Officer. Dr. Beck will remain with the Company in a consulting capacity.
“Tom Beck has played a significant role in building a strong clinical development organization as Dyax moves towards market approval for its lead product candidate. He has helped with the advancement of DX-88 in hereditary angioedema as well as in the positioning of DX-88 for development in the broader cardiothoracic surgery market,” stated Henry Blair, Chairman and Chief Executive Officer of Dyax. “We are thankful for Tom’s contributions and appreciate his willingness to continue to assist us during a transition period.”
